◆ NeutralLLYNVOMCKCORCAH
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool·
Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.
Read Full Article at The Motley Fool →